SCHEMBL209098

SCHEMBL209098

COc1ccc(CN2CCN(C(=O)O)CC2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV6 Q9H1D0 1/20 0.55
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
ATM Q13315 1/20 0.53
PRKAA2 P54646 10/20 0.50
PRKAB2 O43741 2/20 0.50
PRKAG1 P54619 2/20 0.50
PRKAA1 Q13131 2/20 0.50
PRKAG3 Q9UGI9 2/20 0.50
PRKAG2 Q9UGJ0 2/20 0.50
PRKAB1 Q9Y478 2/20 0.50
PIK3CA P42336 10/20 0.48
MLLT1 Q03111 1/20 0.47
GPR183 P32249 1/20 0.46
FAAH O00519 1/20 0.45
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45
PIK3CD O00329 1/20 0.45
PIK3CB P42338 1/20 0.45
MTOR P42345 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2232134 0.85 FAAH (0.46) PRKAA2GPR183FAAHPOLBPKM
SCHEMBL209280 0.84 TBK1 (0.55) TRPV6MEN1KMT2AATMPRKAA2
SCHEMBL16152472 0.83 GPR183 (0.51) TRPV6MEN1KMT2AATMPRKAA2
SCHEMBL14839769 0.82 MEN1 (0.53) TRPV6MEN1KMT2AATMPRKAA2
SCHEMBL18713087 0.81 TRPV6 (0.57) TRPV6MEN1KMT2AHRH3
SCHEMBL18713082 0.81 TRPV6 (0.57) TRPV6PIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL20413614 0.80 TRPV6 (0.56) TRPV6MEN1KMT2AATMPRKAA2
SCHEMBL23589183 0.80 HRH3 (0.67) TRPV6PIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL29259746 0.80 TRPV6 (0.56) TRPV6MEN1KMT2AATMPRKAA2
SCHEMBL21608370 0.79 TBK1 (0.49) TRPV6MEN1KMT2AATMPRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2857388-A1 Azoles containing sulfone Grünenthal GmbH (DE) 2015-04-08 EP disclosed
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 US disclosed
EP-1963315-A2 ENZYME INHIBITORS The Institute of Cancer Research (GB) 2008-09-03 EP disclosed
WO-2007072017-A2 ENZYME INHIBITORS THE INSTITUTE OF CANCER RESEARCH (GB) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247507-A1 Enzyme Inhibitors AURKC, AURKB, AURKA TRPV6 4269/4885MEN1 471/4885KMT2A 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.